Roopa Sethi, MD

Department of Psychiatry, Division Of Addiction Psychiatry, University of Kansas Medical Center, Kansas City, Kansas

  • 24Articles
  • 424.1KReads
  • 2012–2026Active
  • 41Collaborators
  • 103Citations

About

Roopa Sethi, MD is affiliated with Department of Psychiatry, Division Of Addiction Psychiatry, University of Kansas Medical Center, Kansas City, Kansas. Roopa Sethi has authored or co-authored 24 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2012 and 2026. Their work focuses on Addiction, Psychiatry, Schizophrenia/Schizoaffective Disorders, Depression (MDD), and Neurology.

Publications

PCC
Buprenorphine for Pain in Sickle Cell Disease
Review Article

Buprenorphine for Pain in Sickle Cell Disease

June 16, 2026

Buprenorphine is associated with improved functional outcomes as well as reduced ED visits, hospital admissions, and opioid use in patients with chronic pain related to sickle cell disease.
, , , et al
PCC
Neurological Effects of Nitrous Oxide Abuse
Case Report

Neurological Effects of Nitrous Oxide Abuse

July 3, 2025

A 31-year-old woman with a significant history of ketamine and N₂O addiction presented with a complicated range of neurological, neuropsychiatric, and psychiatric symptoms.
, , , et al
PCC
Fentanyl-Contaminated Oxycodone
Narrative Review

Fentanyl-Contaminated Oxycodone

November 9, 2023

The growing use of fentanyl-contaminated products is fueling the US opioid crisis. This study reviewed the rising prevalence of nonprescription fentanyl in counterfeit oxycodone, paying specific attention to oxycodone...
,
PCC
Xylazine as a Fentanyl Adulterant in the US
Narrative Review

Xylazine as a Fentanyl Adulterant in the US

October 31, 2023

Data obtained from studies between 2006 and 2022 indicate a rapidly increasing incidence of xylazine overdose in the United States, with overdose cases now being seen in 25 states.
,
PCC
Opioid Use Disorder and Its Treatment in the Elderly
Systematic Review

Opioid Use Disorder and Its Treatment in the Elderly

January 10, 2023

OUD may be particularly problematic in the elderly due to age-related pain syndromes and comorbidities that increase the risk of side effects, overdose, and death. This review assessed the...
,
PCC
Rapid Microinduction of Buprenorphine in OUD
Case Report

Rapid Microinduction of Buprenorphine in OUD

December 27, 2022

This is the case of a patient who was transitioned from agonist therapy with methadone to sublingual buprenorphine in an outpatient setting in just 3 days.
, ,
PCC
Case Report

Sublingual Buprenorphine Induction and Maintenance for OUD

November 24, 2021

There are multiple factors to consider while initiating medications for opioid use disorder. Mr A is a 66-year-old man with a 17-year history of opioid use for pain management...
, , , et al
PCC
Case Report

Phenibut Dependence and Withdrawal

February 18, 2021

This case report demonstrates the use of benzodiazepines to alleviate the withdrawal symptoms of phenibut in a 26-year-old man who visited the emergency department multiple times.
, ,
PCC
Case Report

Buprenorphine Induction Dosing in Elderly Opioid Use Disorder Patients

September 10, 2020

Here, read about the case of a 73-year-old man who developed hypotension, bradycardia, and possible respiratory depression following buprenorphine induction for opioid withdrawal.
, ,
PCC
Case Report

Prednisone Therapy for Crohn's Disease Enhances Buprenorphine Metabolism

April 23, 2020

Could prednisone therapy for Crohn's disease enhance buprenorphine metabolism, ultimately leading to a false-negative urine drug screen? Read this interesting case report to find out more.
, ,
PCC
Case Report

Tapentadol: An Opioid of Abuse Acquired Online

February 20, 2020

Read a case report to find out more about Tapentadol and how it is often used for pain management, with low abuse potential.
,
PCC
Review Article

Kratom: Friend or Foe?

January 30, 2020

Kratom has gained popularity as an inexpensive and accessible alternative to manage symptoms of opioid use disorder and pain. But, is it safe? This review provides the most up-to-date...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe